KMD Bioscience has many years of research experience in the field of drug antibodies, and has accumulated profound experience in antibody development, aptamer screening, aptamer assay, affinity maturation, etc. KMD Bioscience can provide aptamer screening services for a variety of sample types, such as proteins, peptides, amino acids, small molecular substances, cells and bacteria, metal ions, etc. KMD Bioscience can provide customized in vitro aptamer screening services to ensure efficient, accurate and rapid screening of aptamer sequences required by customers. In addition, KMD Bioscience can provide customers with upstream and downstream services covering aptamer screening, from gene analysis and synthesis, aptamer in vitro screening, aptamer synthesis, aptamer assay, to affinity determination. KMD Bioscience can provide strong support for subsequent functional verification of aptamers (including but not limited to affinity verification, competitive ELISA verification, in vitro targeted cell functional verification (such as in vitro recognition and inhibition function verification of nucleic acid aptamers, in vitro flow cytometry blocking function verification, etc.), and in vivo functional verification (such as in vivo targeted inhibition function verification of aptamers, signal pathway blocking function verification, etc.), laying a solid foundation for subsequent work of customers, such as downstream research and development of targeted specific molecular drugs.

The nucleic acid aptamer screening service based on SELEX technology provided by KMD Bioscience not only includes a variety of types of samples, but also has a variety of aptamer screening methods (magnetic bead SELEX, aptamer cell SELEX, capture SELEX, etc.) to meet the screening needs of different samples. Among them, in the cell targeting aptamers screening, the screening method with whole cells as the target is the most commonly used, that is, aptamer cell selex. KMD Bioscience’s huge aptamer library capacity (10^13-10^14) guarantees the breadth of screening and is sufficient to obtain nucleic acid aptamers for customer targets. After multiple rounds of screening (generally 6-10 rounds), it ensures that high-specific nucleic acid aptamers are obtained, and the binding affinity of aptamers can reach the nM- pM level, far exceeding the standard of conventional aptamers. According to the different needs of each project, KMD Bioscience’s team of scientists can plan the best screening scheme to ensure that the requirements of customers are met.